Top Pharma Q2 2024 Earnings Results by Sabih Beck
Sabih Beck shared on LinkedIn:
“Top Pharma Q2 2024 Earnings Results.
Results show strong performance across major companies, with an emphasis on innovation and expansion.
Pfizer – Strong performance, driven by improved gross margins and higher EPS guidance.
Johnson and Johnson – Strong Pharma growth but mixed performance in MedTech.
Roche – Exceeded expectations, driven by strong Pharmaceuticals and Diagnostics sectors.
Merck – Strong performance with beats in both top-line and EPS, supported by Keytruda and Winrevair.
AbbVie – Positive quarter driven by Skyrizi and Rinvoq; slight underperformance in Aesthetics.
Novartis – Consistent top-line growth with raised guidance for FY24.
Bristol Myers Squibb – Strong quarter led by Revlimid and new product launches like Camzyos.
Sanofi – Strong performance in BioPharma and Consumer Health, with some struggles in Vaccines.
AstraZeneca – Positive quarter led by strong sales in Oncology and CVRM.
GSK – Strong Specialty and General Medicines segments; slight miss in Vaccines.
Takeda – Strong Q2 performance despite some pricing pressures.
Eli Lilly and Company – Significant beat driven by Mounjaro and Zepbound.
Gilead Sciences – Solid quarter with revenue and EPS beats; driven by liver disease portfolio.
Amgen – Revenue increased, driven by strong product sales but faced higher operating expenses.
Novo Nordisk – Robust performance, constrained by supply issues with Wegovy and Ozempic.
Bayer – Mixed results with strong Pharma but weak Crop Science performance.
If you want to receive a complete copy of this report, including top analyst’ firms opinions, please leave a comment below.”
Source: Sabih Beck/LinkedIn
Sabih Beck is the Chief Commercial Officer and Co-Founder of Atacana Group. Previously, he was the Oncology/Hematology Franchise Lead at Roche and served as Director of Global Integrated Insights at Novartis.